

# Michele Magni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7607727/publications.pdf>

Version: 2024-02-01

57  
papers

5,564  
citations

201575

27  
h-index

161767

54  
g-index

57  
all docs

57  
docs citations

57  
times ranked

6722  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells. , 2021, 9, e002240.  |     | 4         |
| 2  | Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. Bone Marrow Transplantation, 2021, 56, 2606-2609.  | 1.3 | 3         |
| 3  | Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 783-791.                  | 0.4 | 35        |
| 4  | Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 332.e19-332.e24.   | 0.8 | 12        |
| 5  | High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. Annals of Oncology, 2015, 26, 167-172.                         | 0.6 | 17        |
| 6  | Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy. Future Oncology, 2014, 10, 2569-2578.   | 1.1 | 8         |
| 7  | Predictors of CD34+ Cell Mobilization and Collection in Adult Men With Germ Cell Tumors: Implications for the Salvage Treatment Strategy. Clinical Genitourinary Cancer, 2014, 12, 196-202.e1.   | 0.9 | 3         |
| 8  | Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against Myc-overexpressing human B-cell non-Hodgkin lymphomas. International Journal of Cancer, 2014, 135, 2034-2045.  | 2.3 | 18        |
| 9  | Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. Bone Marrow Transplantation, 2014, 49, 485-491.   | 1.3 | 10        |
| 10 | Successful second autologous engraftment after long duration storage of hematopoietic stem cells. Bone Marrow Transplantation, 2013, 48, 1480-1481.  | 1.3 | 2         |
| 11 | Long-Term Results of Autologous Hematopoietic Stem-Cell Transplantation After High-Dose <sup>90</sup>Y-Ibritumomab Tiuxetan for Patients With Poor-Risk Non-Hodgkin Lymphoma Not Eligible for High-Dose BEAM. Journal of Clinical Oncology, 2013, 31, 2974-2976. | 0.8 | 14        |
| 12 | Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood, 2011, 118, 4421-4430.  | 0.6 | 30        |
| 13 | Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma. Journal of Clinical Oncology, 2011, 29, 814-824.              | 0.8 | 151       |
| 14 | Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature. Blood, 2010, 115, 2231-2240.   | 0.6 | 32        |
| 15 | Radioimmunotherapy and secondary leukemia: A case report. Leukemia Research, 2010, 34, e1-e4.  | 0.4 | 4         |
| 16 | Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death. Cancer Research, 2010, 70, 9062-9072.  | 0.4 | 126       |
| 17 | Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up. Bone Marrow Transplantation, 2010, 45, 1119-1120.   | 1.3 | 9         |
| 18 | Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leukemia and Lymphoma, 2010, 51, 1251-1259.  | 0.6 | 34        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Clinical Cancer Research</i> , 2009, 15, 4415-4422.   | 3.2 | 189       |
| 20 | High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. <i>Bone Marrow Transplantation</i> , 2009, 43, 509-511.  | 1.3 | 25        |
| 21 | Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. <i>Blood</i> , 2009, 113, 18-27.   | 0.6 | 99        |
| 22 | High-Dose Yttrium-90 <sup>90</sup> Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 5175-5182.  | 0.8 | 68        |
| 23 | Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innovative nei Linfomi Survey. <i>Journal of Clinical Oncology</i> , 2008, 26, 3166-3175.   | 0.8 | 68        |
| 24 | IFN- $\gamma$ Enhances the Antimyeloma Activity of the Fully Human Anti <sup>90</sup> Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3. <i>Cancer Research</i> , 2007, 67, 3269-3275.   | 0.4 | 18        |
| 25 | Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). <i>Leukemia</i> , 2007, 21, 1802-1811. | 3.3 | 66        |
| 26 | Highly efficient gene transfer into mobilized CD34 <sup>+</sup> hematopoietic cells using serotype-5 adenoviral vectors and BoosterExpress Reagent. <i>Experimental Hematology</i> , 2007, 35, 888-897.  | 0.2 | 5         |
| 27 | Placental Growth Factor-1 Potentiates Hematopoietic Progenitor Cell Mobilization Induced by Granulocyte Colony-Stimulating Factor in Mice and Nonhuman Primates. <i>Stem Cells</i> , 2007, 25, 252-261.  | 1.4 | 12        |
| 28 | Antitumor Activity of Human CD34 <sup>+</sup> Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. <i>Human Gene Therapy</i> , 2006, 17, 1225-1240.  | 1.4 | 33        |
| 29 | Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1270-1276.   | 2.0 | 55        |
| 30 | The Anti <sup>90</sup> Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3 Activates the Mitochondrial Cell Death Pathway and Exerts a Potent Antitumor Activity in Lymphoma-Bearing Nonobese Diabetic/Severe Combined Immunodeficient Mice. <i>Cancer Research</i> , 2006, 66, 1799-1808.   | 0.4 | 37        |
| 31 | Antitumor Activity of Human CD34 <sup>+</sup> Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. <i>Human Gene Therapy</i> , 2006, .   | 1.4 | 0         |
| 32 | Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34 <sup>+</sup> -Derived Dendritic Cell Vaccination. <i>Clinical Cancer Research</i> , 2004, 10, 5381-5390.  | 3.2 | 98        |
| 33 | High response rate and manageable toxicity with an intensive, short-term chemotherapy programme for Burkitt's lymphoma in adults. <i>British Journal of Haematology</i> , 2004, 126, 815-820.  | 1.2 | 35        |
| 34 | Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor. <i>Experimental Hematology</i> , 2004, 32, 68-75.   | 0.2 | 7         |
| 35 | Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34 <sup>+</sup> cells in poor mobilizers. <i>Blood</i> , 2004, 103, 3287-3295.  | 0.6 | 47        |
| 36 | Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting. <i>Cancer</i> , 2003, 98, 983-992.   | 2.0 | 18        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). <i>Blood</i> , 2003, 102, 749-755.  | 0.6  | 193       |
| 38 | Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection. <i>Haematologica</i> , 2003, 88, 1396-404.   | 1.7  | 11        |
| 39 | Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2002, 29, S10-S13.  | 1.3  | 28        |
| 40 | Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. <i>Blood</i> , 2002, 100, 1104-1105.  | 0.6  | 58        |
| 41 | Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. <i>Blood</i> , 2002, 99, 3838-3843.  | 0.6  | 2,907     |
| 42 | High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization. <i>Bone Marrow Transplantation</i> , 2002, 30, 725-732. | 1.3  | 47        |
| 43 | Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor. <i>Leukemia Research</i> , 2002, 26, 1131-1133.  | 0.4  | 36        |
| 44 | Defibrotide in combination with granulocyte colony-stimulating factor significantly enhances the mobilization of primitive and committed peripheral blood progenitor cells in mice. <i>Cancer Research</i> , 2002, 62, 6152-7.           | 0.4  | 18        |
| 45 | Large-scale feasibility of gene transduction into human CD34 <sup>+</sup> cell-derived dendritic cells by adenoviral/polycation complex. <i>British Journal of Haematology</i> , 2000, 111, 344-350.                                     | 1.2  | 0         |
| 46 | Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. <i>Blood</i> , 2000, 96, 864-869.                         | 0.6  | 201       |
| 47 | Large-scale feasibility of gene transduction into human CD34 <sup>+</sup> cell-derived dendritic cells by adenoviral/polycation complex. <i>British Journal of Haematology</i> , 2000, 111, 344-350.                                     | 1.2  | 18        |
| 48 | Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. <i>Blood</i> , 2000, 96, 864-869.                         | 0.6  | 1         |
| 49 | Recombinant Adenoviral Vector-LipofectAMINE Complex for Gene Transduction into Human T Lymphocytes. <i>Human Gene Therapy</i> , 1999, 10, 1875-1884.   | 1.4  | 17        |
| 50 | Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis. <i>Bone Marrow Transplantation</i> , 1999, 23, 323-327.  | 1.3  | 19        |
| 51 | Correspondence. <i>Experimental Hematology</i> , 1999, 27, 386-387.  | 0.2  | 2         |
| 52 | Adenovirus vectors for gene transduction into mobilized blood CD34 <sup>+</sup> cells. <i>Gene Therapy</i> , 1998, 5, 465-472.   | 2.3  | 38        |
| 53 | High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 1997, 336, 1290-1298.  | 13.9 | 460       |
| 54 | High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease – A 6-year update. <i>Annals of Oncology</i> , 1993, 4, 889-891.                                      | 0.6  | 61        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Clinical implications of the heterogeneity of hematopoietic progenitors elicited in peripheral blood by anticancer therapy with cyclophosphamide and cytokine(s). <i>Stem Cells</i> , 1993, 11, 72-75.   | 1.4 | 5         |
| 56 | Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients.. <i>Journal of Clinical Oncology</i> , 1992, 10, 1955-1962. | 0.8 | 48        |
| 57 | Practical aspects of flow cytometry to guide large-scale collection of circulating hematopoietic progenitors for autologous transplantation in cancer patients. <i>International Journal of Cell Cloning</i> , 1992, 10, 26-29.  | 1.6 | 4         |